FPX 01

Drug Profile

FPX 01

Alternative Names: FPX01

Latest Information Update: 23 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Centre for Probe Development and Commercialization
  • Class Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Cancer

Most Recent Events

  • 25 Sep 2017 Fusion Pharmaceuticals plans clinical development in 2018
  • 23 Sep 2016 Fusion Pharmaceuticals plans to apply for breakthrough therapy designation for FPX 01 in USA (Fusion Pharmaceuticals pipeline, September 2016)
  • 23 Sep 2016 Fusion Pharmaceuticals announces intention to commercialise FPX 01 in 2019 (Fusion Pharmaceuticals pipeline, September 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top